Plasma levels of matrix metalloproteinases 2 and 9 correlate with histological grade in breast cancer patients

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 316-320

  Vasaturo, Fortunata ^a   Solai, Fabiana ^a   Malacrino, Carolina ^b   Nardo, Tiziana ^b   Vincenzi, Bruno ^c   Modesti, Mauro ^a   Scarpa, Susanna ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Breast cancer; Histological grade; Matrix metalloproteinase; Plasma markers; Tumor grade

Indexed keywords

GELATINASE A; GELATINASE B; STROMELYSIN;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST FIBROADENOMA; CANCER GRADING; CANCER PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 84869066305     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.977     Document Type: Article

References (27)

1. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
2. Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, et al: Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 2: 204-207, 2000.
3. Liotta LA: Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 46: 1-7, 1986.
4. Lynch CC and Matrisan LM: Matrix metalloproteinases in tumor-host cell communication. Differentiation 70: 561-573, 2002.
5. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J and Somiari RI: Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 233: 98-107, 2006.
6. Leppä S, Saarto T, Vehmanen L, Blomqvist C and Elomaa I: A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10: 1057-1063, 2004.
7. Mendes O, Kim HT and Stoica G: Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis 22: 237-246, 2005.
8. Baker EA, Stephenson TJ, Reed MW and Brown NJ: Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 55: 300-304, 2002.
9. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Matrix metalloproteinases in neoplasm-induced extracellular matrix remodelling in breast carcinoma. Anticancer Res 21: 2021-2028, 2001.
10. González LO, Pidal I, Junquera S, Corte MD, Vásquez J, Rodríguez JC, Lamelas ML, Merino AM, García-Muñíz JL and Vizoso FJ: Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 97: 957-963, 2007.
11. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998.
12. Jezierska A and Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 15: RA32-RA40, 2009.
13. Di Carlo A, Terracciano D, Mariano A and Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol 26: 1363-1368, 2005.
14. Staack A, Badendieck S, Schnorr D, Loening SA and Jung K: Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol 6: 19, 2006.
15. Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, Di Trapani D, Gebbia N and Leto G: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastasis to the bone. Anticancer Res 27: 1519-1525, 2007.
16. Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, Stefanescu M and Matache C: MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 10: 499-510, 2006.
17. Stankovic C, Konjevic G, Gopcevic K, Jovic V, Inic M and Jurisic V: Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract 206: 241-247, 2010.
18. Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, Caringella ME, Di Tardo S, Divella R, Trerotoli P, DiGennaro M, Schittulli F, Fransvea E and Giannelli G: MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res 27: 3593-3600, 2007.
19. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E and Puricelli L: Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessement of prognosis in breast cancer patients. Int J Cancer 106: 745-751, 2003.
20. Köhrmann A, Kammerer U, Kapp M, Dietl J and Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 9: 188, 2009.
21. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ and Shao ZM: Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88: 75-85, 2004.
22. Talvensaari-Mattila A, Pääkkö P and Turpeenniemi-Hujanen T: MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 58: 287-293, 1999.
23. Talvensaari-Mattila A, Pääkko P, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 65: 55-61, 2001.
24. Atik E, Akansu B, Bakaris S and Aban N: Expression of cyclooxygenase-2 and its relation to histological grade, inducible nitric oxide synthase, matrix metalloproteinase-2, CD-34, Caspase-3, and CD8 in invasive ductal carcinoma of the breast. Saudi Med J 31: 130-134, 2010.
25. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G and Cohen C: COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 15: 255-259, 2007.
26. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A and Turpeenniemi-Hujanen T: Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 89: 215-220, 2005.
27. de la Torre J, Sabadell MD, Rojo F, Lirola JL, Salaricru S, Reventos J, Ramóny Cajal S and Xercavins J: Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome. Eur J Obstet Gynecol Reprod Biol 151: 72-76, 2010.